vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Bristow Group Inc. (VTOL). Click either name above to swap in a different company.
Bristow Group Inc. is the larger business by last-quarter revenue ($377.3M vs $339.0M, roughly 1.1× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 4.9%, a 8.3% gap on every dollar of revenue. On growth, Bristow Group Inc. posted the faster year-over-year revenue change (6.7% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $47.8M). Over the past eight quarters, Bristow Group Inc.'s revenue compounded faster (5.8% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Bristow Helicopters Limited is a British civil helicopter operator originally based at Aberdeen Airport, Scotland, which is currently a part of the U.S.-based Bristow Group which in turn has its corporate headquarters in Houston, Texas, U.S. In 2020, Bristow Group was merged with Era Helicopters, a large U.S.-based commercial helicopter operator that was previously a division of Era Aviation, with the two companies then continuing to use the Bristow name.
HAE vs VTOL — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $377.3M |
| Net Profit | $44.7M | $18.4M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 8.5% |
| Net Margin | 13.2% | 4.9% |
| Revenue YoY | -2.7% | 6.7% |
| Net Profit YoY | 19.3% | -42.1% |
| EPS (diluted) | $0.95 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $377.3M | ||
| Q3 25 | $327.3M | $386.3M | ||
| Q2 25 | $321.4M | $376.4M | ||
| Q1 25 | $330.6M | $350.5M | ||
| Q4 24 | $348.5M | $353.5M | ||
| Q3 24 | $345.5M | $365.1M | ||
| Q2 24 | $336.2M | $359.7M | ||
| Q1 24 | — | $337.1M |
| Q4 25 | $44.7M | $18.4M | ||
| Q3 25 | $38.7M | $51.5M | ||
| Q2 25 | $34.0M | $31.7M | ||
| Q1 25 | $58.0M | $27.4M | ||
| Q4 24 | $37.5M | $31.8M | ||
| Q3 24 | $33.8M | $28.2M | ||
| Q2 24 | $38.4M | $28.2M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 8.5% | ||
| Q3 25 | 17.9% | 13.1% | ||
| Q2 25 | 16.8% | 11.3% | ||
| Q1 25 | 21.6% | 9.6% | ||
| Q4 24 | 16.9% | 9.0% | ||
| Q3 24 | 15.0% | 9.1% | ||
| Q2 24 | 11.8% | 12.4% | ||
| Q1 24 | — | 6.8% |
| Q4 25 | 13.2% | 4.9% | ||
| Q3 25 | 11.8% | 13.3% | ||
| Q2 25 | 10.6% | 8.4% | ||
| Q1 25 | 17.5% | 7.8% | ||
| Q4 24 | 10.8% | 9.0% | ||
| Q3 24 | 9.8% | 7.7% | ||
| Q2 24 | 11.4% | 7.8% | ||
| Q1 24 | — | 2.0% |
| Q4 25 | $0.95 | $0.61 | ||
| Q3 25 | $0.81 | $1.72 | ||
| Q2 25 | $0.70 | $1.07 | ||
| Q1 25 | $1.17 | $0.92 | ||
| Q4 24 | $0.74 | $1.07 | ||
| Q3 24 | $0.66 | $0.95 | ||
| Q2 24 | $0.74 | $0.96 | ||
| Q1 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $286.2M |
| Total DebtLower is stronger | $1.2B | $671.5M |
| Stockholders' EquityBook value | $911.5M | $1.1B |
| Total Assets | $2.5B | $2.3B |
| Debt / EquityLower = less leverage | 1.34× | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $286.2M | ||
| Q3 25 | $296.4M | $245.5M | ||
| Q2 25 | $292.9M | $251.8M | ||
| Q1 25 | $306.8M | $191.1M | ||
| Q4 24 | $320.8M | $247.5M | ||
| Q3 24 | $299.3M | $200.3M | ||
| Q2 24 | $344.4M | $178.6M | ||
| Q1 24 | — | $140.6M |
| Q4 25 | $1.2B | $671.5M | ||
| Q3 25 | $1.2B | $675.0M | ||
| Q2 25 | $1.2B | $705.2M | ||
| Q1 25 | $1.2B | $701.9M | ||
| Q4 24 | — | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M | ||
| Q1 24 | — | $544.1M |
| Q4 25 | $911.5M | $1.1B | ||
| Q3 25 | $849.2M | $1.0B | ||
| Q2 25 | $882.3M | $984.4M | ||
| Q1 25 | $820.8M | $931.7M | ||
| Q4 24 | $906.9M | $891.7M | ||
| Q3 24 | $878.9M | $899.2M | ||
| Q2 24 | $905.4M | $849.1M | ||
| Q1 24 | — | $820.7M |
| Q4 25 | $2.5B | $2.3B | ||
| Q3 25 | $2.4B | $2.3B | ||
| Q2 25 | $2.5B | $2.3B | ||
| Q1 25 | $2.5B | $2.2B | ||
| Q4 24 | $2.5B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | — | $1.9B |
| Q4 25 | 1.34× | 0.63× | ||
| Q3 25 | 1.44× | 0.65× | ||
| Q2 25 | 1.39× | 0.72× | ||
| Q1 25 | 1.49× | 0.75× | ||
| Q4 24 | — | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $76.9M |
| Free Cash FlowOCF − Capex | $87.2M | $47.8M |
| FCF MarginFCF / Revenue | 25.7% | 12.7% |
| Capex IntensityCapex / Revenue | 1.9% | 7.7% |
| Cash ConversionOCF / Net Profit | 2.09× | 4.17× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $56.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $76.9M | ||
| Q3 25 | $111.3M | $23.1M | ||
| Q2 25 | $17.4M | $99.0M | ||
| Q1 25 | $116.6M | $-603.0K | ||
| Q4 24 | $43.8M | $51.1M | ||
| Q3 24 | $48.8M | $66.0M | ||
| Q2 24 | $-27.4M | $33.7M | ||
| Q1 24 | — | $26.7M |
| Q4 25 | $87.2M | $47.8M | ||
| Q3 25 | $106.3M | $-6.2M | ||
| Q2 25 | $13.6M | $67.4M | ||
| Q1 25 | $100.9M | $-52.7M | ||
| Q4 24 | $35.2M | $-32.4M | ||
| Q3 24 | $39.4M | $9.0M | ||
| Q2 24 | $-33.1M | $-16.7M | ||
| Q1 24 | — | $-37.9M |
| Q4 25 | 25.7% | 12.7% | ||
| Q3 25 | 32.5% | -1.6% | ||
| Q2 25 | 4.2% | 17.9% | ||
| Q1 25 | 30.5% | -15.0% | ||
| Q4 24 | 10.1% | -9.2% | ||
| Q3 24 | 11.4% | 2.5% | ||
| Q2 24 | -9.8% | -4.6% | ||
| Q1 24 | — | -11.2% |
| Q4 25 | 1.9% | 7.7% | ||
| Q3 25 | 1.5% | 7.6% | ||
| Q2 25 | 1.2% | 8.4% | ||
| Q1 25 | 4.7% | 14.9% | ||
| Q4 24 | 2.5% | 23.6% | ||
| Q3 24 | 2.7% | 15.6% | ||
| Q2 24 | 1.7% | 14.0% | ||
| Q1 24 | — | 19.2% |
| Q4 25 | 2.09× | 4.17× | ||
| Q3 25 | 2.88× | 0.45× | ||
| Q2 25 | 0.51× | 3.12× | ||
| Q1 25 | 2.01× | -0.02× | ||
| Q4 24 | 1.17× | 1.61× | ||
| Q3 24 | 1.44× | 2.34× | ||
| Q2 24 | -0.71× | 1.20× | ||
| Q1 24 | — | 4.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
